Reply to A. Katz

Affiliations

¹ N. Lynn Henry, MD, PhD, University of Michigan, Ann Arbor, MI; Fabrice Andre, MD, PhD, Institute Gustave Roussy, Paris Sud University, Paris, France; Nofisat Ismaila, MD; Mark R. Somerfield, PhD, American Society of Clinical Oncology, Alexandria, VA; and Vered Stearns, MD, Johns Hopkins University School of Medicine, Baltimore, MD.

Comment

N Lynn Henry et al. J Clin Oncol. 2020.

. 2020 Jan 1;38(1):102-103.

doi: 10.1200/JCO.19.02431. Epub 2019 Nov 1.

¹ N. Lynn Henry, MD, PhD, University of Michigan, Ann Arbor, MI; Fabrice Andre, MD, PhD, Institute Gustave Roussy, Paris Sud University, Paris, France; Nofisat Ismaila, MD; Mark R. Somerfield, PhD, American Society of Clinical Oncology, Alexandria, VA; and Vered Stearns, MD, Johns Hopkins University School of Medicine, Baltimore, MD.

No abstract available

Comment on

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
Henry NL, Somerfield MR, Abramson VG, Ismaila N, Allison KH, Anders CK, Chingos DT, Eisen A, Ferrari BL, Openshaw TH, Spears PA, Vikas P, Stearns V. Henry NL, et al. J Clin Oncol. 2019 Aug 1;37(22):1965-1977. doi: 10.1200/JCO.19.00948. Epub 2019 Jun 17. J Clin Oncol. 2019. PMID: 31206315
Is It Appropriate to Use the Result of an Unplanned, Exploratory, Nonstatistically Significant Subgroup Analysis to Support a Treatment Recommendation in an ASCO Treatment Guideline?
Katz A. Katz A. J Clin Oncol. 2020 Jan 1;38(1):102. doi: 10.1200/JCO.19.01687. Epub 2019 Nov 1. J Clin Oncol. 2020. PMID: 31675250 No abstract available.